Immunohistochemical subtyping of @entity1149 XXXX in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation.

@entity10922 @entity5 @entity4206 @entity1149 @entity957 @entity2 @entity48451 @entity2433 @entity4205 @entity5822 @entity152 @entity420
BACKGROUND: Histopathological subtyping of @entity1149 ( @entity1149 ) is currently relevant in treatment decision because of a differential activity of specific therapeutic agents. Immunohistochemistry highlights cell differentiation lineages and, in this study, it was applied to maximize the proportion of accurately subtyped @entity1149 @entity2433 ( @entity2433 ) on fine-needle aspiration cytology (FNAC) samples. METHODS: Cell blocks from 103 FNAC samples with a morphological diagnosis of @entity1149 were immunostained for cytokeratin (CK) 7, @entity4205 , @entity10922 , and @entity4206 , whereas @entity4206 , napsin A (Naps-A), and @entity48451 ( @entity48451 ) were only assessed in a subgroup of cases with discordant ( @entity5822 and @entity10922 + for nonsquamous, @entity4205 and @entity4206 + for squamous) findings. Results were correlated with surgical specimens evaluated by morphology alone. RESULTS: Thirty-seven (36%) @entity5 with @entity5822 / @entity10922 + and @entity4205 / @entity4206 - corresponded to 35 cases of @entity420 ( @entity420 ) and 2 cases of @entity152 , whereas 9 (9%) cases with the reverse immunoprofile were @entity957 ( @entity957 ) at surgery (P < .001). Although the remaining 57 cases had different marker combinations, a correlation was found with @entity420 histology for @entity10922 + samples (independent of other markers) and with @entity957 for @entity4206 +/ @entity10922 - immunophenotype (P < .001). @entity4206 was never expressed in @entity4206 + @entity420 , whereas Naps-A was restricted to @entity420 and @entity48451 to @entity957 lineage. The percentage of unclassified @entity1149 decreased from 36% to 14%. Combinations of 2 antibodies ( @entity10922 / @entity48451 or @entity4206 /Naps-A) in the same section allowed diagnostic optimization in scant cytological samples. CONCLUSIONS: [corrected] This 4-antibody panel approach may contribute to refine @entity2 classification in FNAC cell blocks, remarkably reducing the @entity1149 diagnostic category.
